New Warnings for MS Drug Gilenya After FDA Review

April 20, 2012, 7:18 am by WebMD

Novartis, the maker of the drug Gilenya (fingolimod), a once-daily oral capsule taken for multiple sclerosis, has added stronger warnings to labels and prescription information about the drug’s possible heart risks, according to a company statement.

Read the full article

More from WebMD

Genes May Boost Woman's Risk of Postpartum Depression
WebMD : May 21, 2013, 12:16 pm
Test found specific changes to two genes predicted problem with 85 percent accuracy

Losing Weight May Ease Chronic Heartburn
WebMD : May 21, 2013, 12:04 pm
Study found shedding pounds reduced GERD symptoms among overweight, obese patients

Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk
WebMD : May 21, 2013, 11:58 am
Study found 21 percent higher chance of accident among those who slept less than 6 hours a night

Sugar Injections for Knee Arthritis May Ease Pain: Study
WebMD : May 21, 2013, 11:40 am
But at least one expert questions benefits of the alternative treatment

Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer
WebMD : May 21, 2013, 5:44 am
But expert notes questions about frequency remain